Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.44 USD | +4.07% | -9.83% | +0.12% |
Jun. 24 | Replimune Group, Inc.(NasdaqGS:REPL) dropped from S&P Biotechnology Select Industry Index | CI |
Jun. 13 | Replimune Group Signs $100 Million PIPE Deal with Institutional Investors | MT |
Chart calendar Replimune Group, Inc.
Upcoming events on Replimune Group, Inc.
Past events on Replimune Group, Inc.
2024-06-11 02:00 pm | Goldman Sachs Global Healthcare Conference |
2024-06-06 08:00 am | IGNYTE Clinical Trial Update Call |
2024-06-03 11:57 am | American Society of Clinical Oncology Meeting - Abstract #9517 |
2024-06-03 10:57 am | American Society of Clinical Oncology Meeting - Abstract #9511 |
2024-06-01 02:30 pm | American Society of Clinical Oncology Meeting - Abstract #TPS9614 |
2024-06-01 02:30 pm | American Society of Clinical Oncology Meeting - Abstract #TPS9604 |
2024-05-30 | American Society of Clinical Oncology Meeting - Abstract #TPS4191 |
2024-05-16 08:00 am | Q4 2024 Earnings Release |
2024-04-08 09:00 am | American Association for Cancer Research Meeting - Abstract No - 2467 |
2024-04-07 01:00 pm | American Association for Cancer Research Meeting - Abstract No - 9269 |
2024-03-14 10:45 am | Barclays Global Healthcare Conference - Fireside Chat |
2024-03-12 | Jefferies Biotech on the Bay Summit |
2024-03-12 02:20 pm | Leerink Partners Global Biopharma Conference - Fireside Chat |
2024-02-08 08:00 am | Q3 2024 Earnings Release |
2024-01-08 02:15 pm | JPMorgan Healthcare Conference |
2023-12-05 08:00 am | Business Update Call |
2023-11-07 08:00 am | Q2 2024 Earnings Release |
2023-09-06 03:00 pm | Annual General Meeting |
2023-08-08 | Wedbush PacGrow Healthcare Conference |
2023-08-08 01:30 pm | BTIG Biotechnology Conference |
Annual results
Fiscal Period | March | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|---|
Net sales Million USD | Released Forecast Spread | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 5,32 |
EBITDA Million USD | Released Forecast Spread | 0,00 0,00 - | 0,00 0,00 - | -116 -118 1.95% | -175 -176 0.78% | 0,00 0,00 - | -229 |
EBIT Million USD | Released Forecast Spread | -56,2 -57,1 1.55% | -80,0 -78,4 -2.01% | -118 -118 -0.69% | -177 -169 -4.69% | -235 -230 -1.92% | -244 |
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -52,6 -53,2 1.12% | -80,9 -79,6 -1.54% | -118 -117 -0.82% | -174 -169 -2.66% | -215 -217 0.74% | -244 |
Net income Million USD | Released Forecast Spread | -52,6 -53,2 1.06% | -80,9 -79,6 -1.6% | -118 -117 -0.83% | -174 -169 -2.85% | -216 -217 0.69% | -238 |
EPS USD | Released Forecast Spread | -1,54 -1,57 2% | -1,75 -1,76 0.43% | -2,26 -2,28 0.72% | -2,99 -2,91 -2.78% | -3,24 -3,23 -0.31% | -3,28 |
Announcement Date | 03/06/20 | 20/05/21 | 19/05/22 | 18/05/23 | 16/05/24 | - |
Quarterly results
Fiscal Period | March | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 | 2025 Q3 | 2025 Q4 | 2026 Q1 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales Million USD | Released Forecast Spread | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
EBIT Million USD | Released Forecast Spread | -32,0 -31,2 -2.44% | -40,9 -33,4 -22.55% | -41,6 -42,6 2.35% | -41,6 -43,2 3.61% | -53,0 -44,0 -20.57% | -55,6 -54,1 -2.8% | -63,8 -57,1 -11.84% | -56,5 -64,3 12.11% | -58,8 -56,1 -4.8% | -62,3 | -61,3 | -62,1 | -63,0 | -64,4 |
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -31,7 -30,7 -3.39% | -42,3 -32,9 -28.58% | -43,1 -42,1 -2.47% | -39,7 -42,7 7.11% | -49,0 -42,2 -15.9% | -49,4 -51,8 4.69% | -60,2 -55,8 -7.98% | -50,6 -60,6 16.43% | -55,1 -52,9 -4.17% | -60,4 | -61,6 | -62,5 | -63,8 | -62,2 |
Net income Million USD | Released Forecast Spread | -31,7 -30,7 -3.37% | -42,3 -32,9 -28.5% | -43,1 -42,0 -2.54% | -39,7 -42,8 7.32% | -49,2 -43,1 -14.28% | -49,6 -51,8 4.3% | -60,0 -54,6 -9.97% | -51,1 -61,7 17.11% | -55,1 -53,6 -2.78% | -59,6 | -60,0 | -60,0 | -60,4 | -62,2 |
EPS USD | Released Forecast Spread | -0,60 -0,60 -0.66% | -0,78 -0,63 -24.06% | -0,79 -0,78 -0.99% | -0,69 -0,77 10.39% | -0,74 -0,69 -7.59% | -0,75 -0,84 10.84% | -0,90 -0,86 -4.48% | -0,77 -0,94 17.77% | -0,25 -0,80 68.91% | -0,87 | -0,84 | -0,86 | -0,83 | -0,68 |
Announcement Date | 19/05/22 | 04/08/22 | 03/11/22 | 09/02/23 | 18/05/23 | 03/08/23 | 07/11/23 | 08/02/24 | 16/05/24 | - | - | - | - | - |
2024-07-15 01:45 am | ADDLIFE AB: Q2 2024 Earnings Release |
2024-07-21 | MEDPACE HOLDINGS, INC.: Q2 2024 Earnings Release |
2024-07-23 | SYNGENE INTERNATIONAL LIMITED: Q1 2025 Earnings Release |
2024-07-23 | ALKERMES PLC: Q2 2024 Earnings Release (Projected) |
2024-07-23 | IQVIA HOLDINGS INC.: Q2 2024 Earnings Release (Projected) |
2024-07-23 | ICON PUBLIC LIMITED COMPANY: Q2 2024 Earnings Release |
2024-07-24 | LONZA GROUP AG: Q2 2024 Earnings Release |
2024-07-25 01:00 am | BACHEM HOLDING AG: Q2 2024 Earnings Release |
2024-07-25 | PHARVARIS N.V.: Q2 2024 Earnings Release (Projected) |
2024-07-26 01:00 am | BB BIOTECH AG: Q2 2024 Earnings Release |
Past sector events for Replimune Group, Inc.
2024-06-07 02:57 am | POLARIS GROUP: May 2024 Sales and Revenue Release |
2024-05-29 04:01 pm | IMMUNOVANT, INC.: Q4 2024 Earnings Release |
2024-05-23 07:00 am | CUREVAC N.V.: Q1 2024 Earnings Release |
2024-05-22 01:00 am | EVOTEC SE: Q1 2024 Earnings Release |
2024-05-21 05:14 pm | ALVOTECH: Q1 2024 Earnings Release |
2024-05-21 07:00 am | EXSCIENTIA PLC: Q1 2024 Earnings Release |
2024-05-17 02:00 am | BIOARCTIC AB: Q1 2024 Earnings Release |
2024-05-15 04:05 pm | CULLINAN THERAPEUTICS, INC.: Q1 2024 Earnings Release |
2024-05-15 07:00 am | PERSPECTIVE THERAPEUTICS, INC.: Q1 2024 Earnings Release |
2024-05-14 | GNI GROUP LTD.: Q1 2024 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- REPL Stock
- Calendar Replimune Group, Inc.